These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
This drug has been approved for the treatment of multiple chronic inflammatory disorders.
Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.
A new naloxone nasal spray will soon be available.
Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.
As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.
Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.
While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.
